Best Immunotherapy Companies in Cambridge, United States

Developer of antibody therapies for cancer treatment. The company is advancing the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).

Funding rounds

• Mar 2026Series B$77M
• Sep 2025Series A$30.2M
• Jul 2023Series A$80M

Founders & team

Geraldine PaulusCo-FounderBriggs MorrisonCEO

Investors

Pfizer, Polaris Partners, BVF Partners, Mirae Asset Venture Investments, Mirae Asset, Lilly

Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.

Developer of immunotherapeutics for immunological and cancer diseases. It offers anti-inflammation immunotherapies such as anti-TNF antibodies and JAK inhibitors for inflammatory diseases and cancer. It has a computational drug discovery platform.

Funding rounds

• Jun 2025Series D$214M
• Oct 2023Series C$117.2M
• Oct 2022Series B$168M
• Dec 2021Series A$218M

Founders & team

Paul-Albert KönigCo-Founder and Sr. Director BiologyCharlie KoniverCo-FounderGary GlickCo-Founder & CEO

Investors

General Catalyst, Alexandria, Walleye, Catalio Capital Management, GreatPoint Ventures, SVB Securities

Tech stack

Apple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCookieyesCore-Js

Developer of B cell therapies for multiple therapeutic areas. The company uses proprietary autologous and allogeneic BeCM platforms across multiple therapeutic areas and progress pipeline candidates mainly on oncology and rare diseases. Also, it advances its platform into additional therapeutic areas including infectious disease, neurological conditions, and autoimmune disease.

Developing targeted and immuno-oncology therapeutics for cancer patients. Focused on advancing cancer treatment through innovative therapies, the company develops humanized monoclonal antibodies. Their pipeline includes programs targeting proteins like DKK1 and GDF-15, with clinical candidates in development for esophagogastric, gynecologic, and colorectal cancers. They are dedicated to understanding tumor expression and creating new targets and combinations. The company is committed to stopping cancer through new therapies. They are working towards expanded access for patients. The company is involved in research and development, clinical trials, and regulatory affairs.

Developer of therapeutic solutions for treating multiple neurodegenerative diseases. The company is developing microglia-focused therapeutic solutions to treat rare and common neurodegenerative diseases. The lead candidate VGL101 is a monoclonal antibody agonist of TREM2, a transmembrane receptor expressed selectively on microglia.

Funding rounds

• Jul 2024Post IPO$40M
• Aug 2021Series B$90M
• Dec 2020Series A$50M

Founders & team

Ivana LiebischCEO & President

Investors

Vida Ventures, Hatteras Venture Partners, Citadel, Orbimed, Deep Track Capital, Invus

Developer of cell therapies for autoimmune and inflammatory disease. The company is developing regulatory T cells as targeted therapies that stop immune-mediated destruction and restore homeostasis. It is used for the treatment of progressive multiple sclerosis, type-1 diabetes, and inclusion body myositis.

Funding rounds

• Aug 2024Series A—
• Dec 2023Series A$15.3M
• Jun 2021Series A$95M

Founders & team

Samantha SingerPresident & Chief Executive Officer

Investors

Bristol-Myers Squibb, Third Rock Ventures, ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital

Developer of engineered cell and gene therapies for multiple diseases. The lead candidate cytoTIL15 is used for melanoma, HNSCC, cervical cancer, solid tumors, other candidates include cytoTILx-1 and cytoTILx-2, CD40L, and IL-12 for other disorders. The company's cytoDRiVE platform leverages drug-responsive domains to control protein function.

Funding rounds

• Apr 2024Series C$160.5M
• Sep 2021Series B$115M
• Dec 2017Series A$49.5M

Founders & team

Michael GilmanCEO

Investors

Wellington, Foresite Capital, Janus Henderson Investors, Novo Holdings, Paradigm BioCapital, RTW Investments

Tech stack

AosApple Icloud MailBootstrapCookieyesCore-JsGodaddy

Developer of modality-agnostic targeted therapeutics for cancer and autoimmune indications. The company is developing a diversified portfolio of clinical-stage assets that inhibit key drivers of disease and harnesses the immune system to eliminate diseased cells in both oncology and autoimmune diseases.

Funding rounds

• Apr 2024Post IPO$280M

Founders & team

Karl WittrupCo-founderNora OuamaniExecutive Assistant To Chief Executive Officer

Investors

Adage Capital Management, Avidity Partners, Blue Owl, Boxer Capital, Braidwell, BVF Partners

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Developer of immunetherapeutics for immune-disorders. It offers iPSC-derived thymic cells -based therapeutics to restore normal immune function and treat immunodeficiencies, transplant-related, and autoimmune disorders.

Funding rounds

• Apr 2025Grant (prize money)$2.6M
• Jan 2025Grant (prize money)$2.6M
• Mar 2023Seed$7M
• Apr 2022Grant (prize money)$1.6M

Founders & team

Stan WangFounder & CEO

Investors

Pillar VC, NYBC Ventures, HHS

Developer of antibody-drug conjugates to treat cancer and cardiovascular diseases. The company is developing an antibody platform targeting TM4SF1, to develop a cancer biotherapeutic internally, and will out-license its antibodies to pharma and biotech partners for vascular indications. TM4SF1 is a transmembrane signal transduction protein (they play a role in the regulation of cell development, activation, growth, and motility) commonly overexpressed in carcinomas. The company is testing the drug in animal models currently.

Funding rounds

• Jul 2025Series B$31M
• Aug 2021Series B$45M
• Jul 2017Seed$3M
• Nov 2016Grant (prize money)$500K

Founders & team

Paul JaminetFounder & CEO

Investors

MassChallenge, Boeing, Starling Ventures, Wild Ventures, Presight Capital, Gaingels

Tech stack

Craft CmsDocusignGodaddyGsapHttp/3Lit-Element

Developer of drugs for treating autoimmune disorders. It is developing drugs for restoring immune homeostasis to treat severe inflammatory and autoimmune diseases. The company has developed drugs such as ADX-914, ADX-097, novel fusion proteins, and therapies to target the innate and adaptive immune systems.

Funding rounds

• Mar 2024Post IPO$42M
• Oct 2020Series B$60M
• May 2020Series A$46M

Founders & team

Shelia VioletteFounder & CSO

Investors

Atlas Venture, Orbimed, Abingworth, Sanofi Ventures, Children's Hospital Colorado, University of Colorado